Broadly Neutralizing Neuraminidase Antibodies for Prophylactic and Therapeutic Treatment of Influenza
SUMMARY One of the weaknesses of current influenza vaccines is seasonable variability in efficacy, which is predominantly caused by escape mutations in the hemagglutinin (HA) antigen, the main target of the vaccine-induced immune response. Only 1-2% of vaccine-induced antibodies target the neuraminidase (NA) antigen, despite this antigen being less susceptible… Read More